← All drugs Report issue

ro7121661

mAbexperimentalMulti-specific

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

1

Phase 3

0

Phase 4

0

Earliest trial started Oct 15, 2018 (NCT03708328)

Timeline

2010s

Jan 1, 2018
Earliest Phase 1 Sponsor(trial)

2020s

Jan 1, 2021
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
- Programmed cell death protein 1 (PDCD1) ↗
Hepatitis A virus cellular receptor 2INHIBITOR
HAVCR2 inhibitor
- Hepatitis A virus cellular receptor 2 (HAVCR2) ↗

Chemistry & pharmacology

Multi-specific: Yes

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT04785820	Phase 2	Jun 25, 2021	Roche
NCT03708328	Phase 1	Oct 15, 2018	Roche

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Roche	For profit	2	2	2	2018

1 organizations

Page 1 / 1